Complement

Critical Care Medicine

Volumn 33, Issue 12 SUPPL., 2005, Pages

  Goldfarb, Roy D ^a   Parrillo, Joseph E ^a,b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Department of Anesthesiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIUM LIPOPOLYSACCHARIDE; C REACTIVE PROTEIN; COMPLEMENT; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A; DNA; NEUTRALIZING ANTIBODY; POLYANION; POLYSACCHARIDE; RECOMBINANT DNA; RECOMBINANT PROTEIN; RNA; SERUM AMYLOID P; TRYPSIN;

AUTOIMMUNE DISEASE; BACTERIAL MEMBRANE; COMPLEMENT ACTIVATION; CRITICAL ILLNESS; DRUG MECHANISM; FUNGUS; GENE THERAPY; HEALTH STATUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPSIS; SOLUBILITY; VIRUS ENVELOPE;

EID: 28944439134     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000186789.27047.84     Document Type: Article

References (15)

1. Roitt I: Essential Immunology. Ninth Edition. Blackwell Scientific, 1997
2. Guo R-F, Ward PA: Role of C5a in inflammatory responses. Annu Rev Immunol 2005. 23:821-852
3. Gaboriaud C, Thielens NM, Gregory LA, et al: Structure and activation of the C1 complex of complement: Unraveling the puzzle. Trends Immunol 2004; 25:368-373
4. de Boer JP, Creasey AA, Chang A, et al: Activation of the complement system in baboons challenged with live Escherichia coli: Correlation with mortality and evidence for a biphasic activation pattern. Infect Immun 1993; 61:4293-4301
5. Windbichler M, Echtenacher B, Hehlgans T, et al: Involvement of the lectin pathway of complement activation in antimicrobial immune defense during experimental septic peritonitis. Infect Immun 2004; 72:5247-5252
6. Huber-Lang M, Sarma JV, Rittirsch D, et al: Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans. J Immunol 2005; 174:1104-1110
7. Jansen PM, Eisele B, de Jong IW, et al: Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol 1998; 160:475
8. Liu D, Cai S, Gu X, et al: C1 Inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J Immunol 2003; 171:2594-2601
9. Fischer MB, Prodeus AP, Nicholson-Weller A, et al: Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement. J Immunol 1997; 159:976
10. Guo RF, Riedemann NC, Ward PA: Role of C5a-C5aR interaction in sepsis. Shock 2004; 21:1-7Jan.
11. Ember JA, Hugli TE: Complement factors and their receptors. Immunopharmacology 1997; 378:3-15
12. Buras JA, Rice L, Orlow D, et al: Inhibition of C5 or absence of C6 protects from sepsis mortality. Immunobiology 2004; 209:629-634
13. Quigg RJ: Use of complement inhibitors in tissue injury. Trends Mol Med 2002; 8:430-436
14. Mizuno M, Nishikawa K, Okada N, et al: Soluble complement receptor type 1 protects rats from lethal shock induced by anti-Crry antibody following lipopolysaccharide priming. Int Arch Allergy Immunol 2002; 127:55-62
15. Hangen DH, Stevens JH, Satoh PS, et al: Complement levels in septic primates treated with anti-C5a antibodies. J Surg Res 1989; 46:195-199